<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00410501</url>
  </required_header>
  <id_info>
    <org_study_id>CQAB149A2311</org_study_id>
    <nct_id>NCT00410501</nct_id>
  </id_info>
  <brief_title>Evaluation of Pharmacokinetic Interaction of Indacaterol With Ketoconazole in Healthy Adult Subjects</brief_title>
  <official_title>An Open Label, Single Dose, Two Period, Single Sequence Crossover Study to Assess the Pharmacokinetic Interaction of QAB149 (300 Mcg Via Inhalation) With Ketoconazole (200 mg Tablet b.i.d.) in Healthy Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the interaction potential between indacaterol and ketoconazole (a
      potent CYP3A inhibitor) in healthy adult subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2006</start_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics of a single 300 µg dose of indacaterol (QAB149) alone administered via inhalation and in the presence of ketoconazole (at steady state) in healthy adult subjects</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety of a single 300 µg dose of indacaterol (QAB149) given via inhalation in the presence of ketoconazole at steady state in healthy adult subjects.</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Healthy</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Indacaterol (QAB149)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy, male or female subjects of Indian origin age 18 to 45 years of age
             (inclusive)

          -  In good health as confirmed by past medical history, physical examination,
             electrocardiogram, laboratory tests and urinalysis on the screening and baseline
             evaluation

          -  Female subjects must be either surgically sterilized at least 6 months prior to study
             participation or post-menopausal (no regular menstrual bleeding for at least 2 years),
             or using a double-barrier local contraception if of childbearing potential

          -  Body mass index (BMI) within the range of 18.5 to 27 kg/m2 and weigh at least 45 kg
             for females and 50 kg for males

        Exclusion Criteria:

          -  Smokers (use of tobacco products in the previous 3 months).

          -  Using or planning to use medications affecting GI (gastrointestinal) motility and/or
             perception (prokinetics, antidiarrheals, antispasmodics, anticholinergics, antacids
             containing magnesium or aluminum salts, erythromycin, octreotide, ondansetron or other
             5-HT3 antagonists).

          -  Use of any prescription drugs within 4 weeks prior to dosing, or over-the-counter
             (OTC) medication (vitamins, herbal supplements, dietary supplements) within two (2)
             weeks prior to dosing. Paracetamol (up to 4 g daily) is acceptable

          -  Participation in any clinical investigation within 4 weeks prior to dosing or longer
             if required by local regulations, and for any other limitation of participation based
             on local regulations.

          -  Donation or loss of 400 mL or more of blood within 8 weeks prior to first dosing or
             longer if required by local regulation.

          -  Significant illness within two weeks prior to dosing.

          -  A past medical history of clinically significant ECG abnormalities. Significant
             history of psychiatric disorder.

          -  History of clinically significantfainting, low blood pressure when standing, irregular
             heart beats or acute or chronic bronchospastic disease (including asthma and chronic
             obstructive pulmonary disease, treated or untreated) drug allergy or history of atopic
             allergy (asthma, urticaria, eczematous dermatitis, nasal polyp or NSAID (non-steroidal
             anti-inflammatory drug) induced urticaria)

          -  A known hypersensitivity or severe adverse event to indacaterol/ketoconazole or drugs
             similar to the study drugs.

          -  History of bowel obstruction, symptomatic gall bladder disease, suspected Sphincter of
             Oddi dysfunction, or abdominal adhesions.

          -  Any surgical or medical condition which might significantly alter the absorption,
             distribution, metabolism or excretion of drugs or which may jeopardize the subject in
             case of participation in the study.

          -  History of immunodeficiency diseases, including a positive HIV (ELISA and Western
             blot) test result.

          -  Any planned surgery or procedure within 3 months of screening.

          -  A positive Hepatitis B surface antigen (HBsAg) or Hepatitis C or VDRL (Venereal
             Disease Research Laboratory) test result.

          -  History of drug or alcohol abuse within the 6 months prior to dosing or evidence of
             such abuse as indicated by the laboratory assays conducted during the screening or
             baseline evaluations. Consumption of alcohol within 48 hours of receiving medication.

        Other protocol-defined inclusion/exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis</last_name>
    <role>Study Director</role>
    <affiliation>Investigator site</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis</name>
      <address>
        <city>Mumbai</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>June 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 12, 2006</study_first_submitted>
  <study_first_submitted_qc>December 12, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 13, 2006</study_first_posted>
  <last_update_submitted>June 18, 2007</last_update_submitted>
  <last_update_submitted_qc>June 18, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 19, 2007</last_update_posted>
  <keyword>Pharmacokinetics, interaction, QAB149, indacaterol, ketoconazole, healthy subjects</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketoconazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

